PA8846801A1 - Composiciones farmacéuticas que contienen diacereína - Google Patents

Composiciones farmacéuticas que contienen diacereína

Info

Publication number
PA8846801A1
PA8846801A1 PA20098846801A PA8846801A PA8846801A1 PA 8846801 A1 PA8846801 A1 PA 8846801A1 PA 20098846801 A PA20098846801 A PA 20098846801A PA 8846801 A PA8846801 A PA 8846801A PA 8846801 A1 PA8846801 A1 PA 8846801A1
Authority
PA
Panama
Prior art keywords
pharmaceutical compositions
compositions containing
diacerein
containing diacerein
treat
Prior art date
Application number
PA20098846801A
Other languages
English (en)
Inventor
Gao Danchen
Wu Jen-Sen
Wei-Shu-Lu
Chen Shouchiung
Kuo Pei-Chun
Chen Chih-Ming
Original Assignee
Anchen Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anchen Lab Inc filed Critical Anchen Lab Inc
Publication of PA8846801A1 publication Critical patent/PA8846801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DIVULGA UNA ÚNICA FORMULACIÓN DIARIA DE LIBERACIÓN CONTROLADA DE DIACEREÍNA PARA TRATAR ENFERMEDADES INFLAMATORIAS O AUTOINMUNES O SUS COMPLICACIONES, CON EFECTOS COLATERALES ADVERSOS REDUCIDOS, Y MÉTODOS PARA TRATAR DICHAS ENFERMEDADES.
PA20098846801A 2008-10-28 2009-10-28 Composiciones farmacéuticas que contienen diacereína PA8846801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10893108P 2008-10-28 2008-10-28

Publications (1)

Publication Number Publication Date
PA8846801A1 true PA8846801A1 (es) 2010-05-26

Family

ID=42117735

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098846801A PA8846801A1 (es) 2008-10-28 2009-10-28 Composiciones farmacéuticas que contienen diacereína

Country Status (19)

Country Link
US (2) US20100104651A1 (es)
EP (1) EP2349289B1 (es)
JP (1) JP5642691B2 (es)
KR (1) KR101718347B1 (es)
CN (1) CN102202673B (es)
AR (1) AR073918A1 (es)
AU (1) AU2009308958B2 (es)
BR (1) BRPI0920255A2 (es)
CA (1) CA2741846C (es)
ES (1) ES2585904T3 (es)
IL (1) IL212483A (es)
MX (1) MX2011004395A (es)
NZ (1) NZ592376A (es)
PA (1) PA8846801A1 (es)
RU (1) RU2542461C2 (es)
SA (1) SA109300644B1 (es)
TW (1) TWI473610B (es)
UY (1) UY32204A (es)
WO (1) WO2010051296A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2560310T3 (es) * 2010-04-08 2016-02-18 Twi Biotechnology, Inc. Métodos de uso de diacereína como una terapia concomitante para diabetes
CN101822660B (zh) * 2010-05-13 2013-07-10 中国人民解放军肾脏病研究所 大黄酸类化合物或其盐在制备预防和治疗胰岛β细胞功能衰退药物中的应用
RU2603050C2 (ru) * 2011-03-11 2016-11-20 ТиДаблЮАй БАЙОТЕКНОЛОДЖИ, ИНК. Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией
CN102743370B (zh) * 2011-06-27 2013-05-15 王子厚 双醋瑞因的用途
EP2760473A1 (en) 2011-09-27 2014-08-06 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
US20140336148A1 (en) * 2011-12-27 2014-11-13 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combinations of diacerein and non-steroidal inflammation drugs
US20150004229A1 (en) * 2011-12-27 2015-01-01 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combined pharmaceutical formulation containing diacerein
CN102871982B (zh) * 2012-10-16 2014-09-10 中国科学院上海药物研究所 一种药物渗透泵制剂
US11198724B2 (en) * 2013-03-14 2021-12-14 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
MX2017013489A (es) * 2015-04-20 2018-05-22 Twi Biotechnology Inc Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos.
US10512625B2 (en) * 2015-07-01 2019-12-24 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
US10154984B2 (en) * 2015-07-01 2018-12-18 Twi Biotechnology, Inc. Diacerein or Rhein topical formulations and uses thereof
AU2016287636B2 (en) * 2015-07-01 2021-09-16 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
US10195170B2 (en) * 2015-08-17 2019-02-05 Twi Biotechnology, Inc. Methods for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex using diacerein or its analogs
AU2018210771B2 (en) * 2017-01-18 2020-04-02 Tairx, Inc. Compositions for use in treating inflammatory bowel diseases and intestinal colitis
KR102563841B1 (ko) * 2017-01-19 2023-08-03 티더블유아이 바이오테크놀로지 인코포레이티드 면역염증성 피부 장애를 예방 또는 치료하기 위한 방법 및 약학적 조성물
CN107929264B (zh) * 2017-12-04 2020-04-24 广东药科大学 双醋瑞因缓释微球及其制备方法
KR102075724B1 (ko) * 2018-09-14 2020-02-10 한국원자력의학원 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도
CN110787157A (zh) * 2019-11-27 2020-02-14 中南民族大学 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用
CN113440503B (zh) * 2021-07-02 2022-03-18 温州医科大学附属口腔医院 超长效可控缓释介孔-透明质酸杂化靶向抗菌纳米材料及其制备方法、用途
CN115227664A (zh) * 2022-06-27 2022-10-25 苏州中化药品工业有限公司 一种双醋瑞因胶囊及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) * 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
US5225192A (en) * 1988-10-17 1993-07-06 Vectorpharma International S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
US5569469A (en) * 1984-10-16 1996-10-29 Vectorpharma International, S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
IT1197316B (it) * 1986-10-01 1988-11-30 Proter Spa Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico
IT1230566B (it) * 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5840881A (en) * 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
RU2128499C1 (ru) * 1992-12-23 1999-04-10 Сайтек С.Р.Л. Способ получения фармацевтических форм с контролированным высвобождением действующего вещества и формы, полученные данным способом
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
US6197818B1 (en) * 1998-09-01 2001-03-06 Nanjing General Hospital Of Nanjing Command, Pla Drug for treating diabetic nephrosis
BR0211948A (pt) * 2001-08-25 2004-09-14 Arakis Ltd O uso de antraquinonas no tratamento de doenças dos rins
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
MXPA05001707A (es) * 2002-08-30 2005-04-19 Pharmacia Corp Formas de dosificacion farmaceutica solidas que presentan un perfil de liberacion de farmaco reproducible,.
WO2004066981A1 (en) * 2003-01-29 2004-08-12 Sun Pharmaceutical Industries Limited Oral controlled release pharmaceutical composition containing metaxalone as active agent
MXPA04009698A (es) * 2004-10-04 2006-04-05 Maria Elena Garcia Armenta Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam.
CN1748675A (zh) * 2005-07-11 2006-03-22 丛晓东 大黄酸类化合物的复合物及制备方法与治疗糖尿病的应用
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN100475201C (zh) * 2007-03-19 2009-04-08 上海慈瑞医药科技有限公司 二乙酰大黄酸缓释片的制备方法
NZ586091A (en) * 2007-09-27 2012-05-25 Wockhardt Research Center Pharmaceutical compositions of rhein or diacerein
WO2009048940A2 (en) * 2007-10-08 2009-04-16 Dr. Reddy's Laboratories Ltd. Diacerein pharmaceutical formulations

Also Published As

Publication number Publication date
AR073918A1 (es) 2010-12-09
KR101718347B1 (ko) 2017-03-21
MX2011004395A (es) 2011-08-03
EP2349289A1 (en) 2011-08-03
AU2009308958A1 (en) 2010-05-06
CN102202673A (zh) 2011-09-28
AU2009308958B2 (en) 2016-05-19
JP5642691B2 (ja) 2014-12-17
SA109300644B1 (ar) 2014-10-28
EP2349289A4 (en) 2013-12-04
CA2741846A1 (en) 2010-05-06
CA2741846C (en) 2018-03-27
ES2585904T3 (es) 2016-10-10
IL212483A (en) 2017-10-31
US20130156857A1 (en) 2013-06-20
CN102202673B (zh) 2013-07-31
KR20110081316A (ko) 2011-07-13
NZ592376A (en) 2012-12-21
BRPI0920255A2 (pt) 2016-01-05
RU2542461C2 (ru) 2015-02-20
UY32204A (es) 2010-05-31
TWI473610B (zh) 2015-02-21
JP2012506911A (ja) 2012-03-22
IL212483A0 (en) 2011-06-30
TW201018461A (en) 2010-05-16
US20100104651A1 (en) 2010-04-29
EP2349289B1 (en) 2016-07-13
RU2011121609A (ru) 2012-12-10
WO2010051296A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
PA8846801A1 (es) Composiciones farmacéuticas que contienen diacereína
SV2011003798A (es) Salicilatos acetilados con acidos grasos y sus usos
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
NI201100056A (es) Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyética y su uso para tratar enfermedades mediadas por prostaglandina d2.
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
ECSP12012097A (es) Derivados de fumarato de ácido graso y sus usos
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
HN2011001810A (es) Sintesis de espirikpiridinas radiomarcadas con 18f a partir de precursores de tosilato y composiciones farmaceuticas estables de estas.
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
AR075442A1 (es) Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
BR112012012399B8 (pt) Composições para ruptura de biofilme, artigo ou dispositivo e método para ruptura de biofilmes
CR20110407A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
CR20110560A (es) Métodos de tratamiento para tumores sólidos
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112012020989A2 (pt) composições veterinárias
CL2008001835A1 (es) Uso de compuestos derivados de guaninas policiclicas para tratar la inflamacion; compuestos derivados de guanina; y compocicion farmaceutica que los comprende.
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
CL2009001139A1 (es) Composicion que comprende un lisofosfolipido para tratar los efectos de la inflamacion.
AR098900A1 (es) Composiciones y métodos para el cuidado oral
MY195384A (en) Two-Component Composition
BR112013016998A2 (pt) emplastro medicamentoso para a permeação transdérmica melhorada de diclofenaco dietilamônio
AR098772A1 (es) Composiciones para cuidado oral y métodos